Recombinant Factor IX Production with PACE, VKOR, and VKGC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing recombinant technologies for producing vitamin K-dependent proteins, such as Factor IX, are limited by the inability to achieve adequate post-translational modifications, resulting in low levels of fully functional protein and high production costs, making them inaccessible to many regions worldwide.
Innovation Solution
A method involving the co-expression of genes encoding vitamin K-dependent proteins with paired basic amino acid converting enzyme (PACE), vitamin K-dependent epoxide reductase (VKOR), and vitamin K-dependent γ-glutamyl carboxylase (VKGC) in mammalian cells, optimized by using a Chinese hamster elongation factor 1-α (CHEF1) promoter, to enhance gamma-carboxylation and produce biologically active proteins at levels suitable for commercial use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant technologies are used to produce vitamin K-dependent proteins, then production costs increase and functional protein levels remain low, but if traditional methods are used, then pathogen contamination risks increase
Solution Approach 1:
The patent combines multiple processing enzymes (PACE, VKOR, VKGC) into a single recombinant expression system within mammalian cells. This merging of functions allows the cell to simultaneously perform propeptide removal, vitamin K epoxide reduction, and gamma-carboxylation, achieving high levels of fully functional protein (≥15 mg/L) while maintaining safety from pathogen contamination through recombinant production.
2Reliability
If recombinant production methods are used, then pathogen contamination risk decreases, but post-translational modification capabilities are insufficient, resulting in low functional protein levels
Solution Approach 1:
The patent merges three separate processing functions (PACE for propeptide conversion, VKOR for epoxide reduction, and VKGC for gamma-carboxylation) into a single recombinant expression system. This allows the mammalian cell to perform all necessary post-translational modifications internally, achieving ≥90% gamma-carboxylation and high levels of fully functional protein while maintaining the safety advantages of recombinant production.
Solution Approach 2:
The patent introduces exogenous processing enzymes (PACE, VKOR, VKGC) as intermediaries to bridge the gap between the cell's native capabilities and the required post-translational modifications. These intermediary enzymes enable the recombinant system to achieve proper protein processing and activation that would otherwise be insufficient in standard recombinant expression systems.
3Ease of manufacture
If standard recombinant expression systems are used, then production is simpler, but the ability to perform complete post-translational modifications is lacking
Solution Approach 1:
The patent combines multiple processing enzyme genes (PACE, VKOR, VKGC) with the vitamin K-dependent protein gene in a single recombinant expression system. This merged approach maintains the simplicity of recombinant expression while enabling complete post-translational modifications, resulting in high yields of biologically active protein (≥15 mg/L) without requiring complex multi-step processing systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the yield of fully functional vitamin K-dependent proteins, such as Factor IX, to at least 15 mg/L, ensuring a higher percentage of biologically active protein, thereby reducing production costs and making them more accessible globally.
Implementation Method 1
transfecting a mammalian cell with a gene encoding a vitamin K dependent protein operably linked to a promoter
Implementation Method 2
transfecting a mammalian cell with a gene encoding a vitamin K dependent protein operably linked to a promoter
Implementation Method 3
co-expression of one or more proteins involved in the processing of the vitamin K dependent proteins. These processing proteins include paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide redactase (VKOR)
Implementation Method 4
co-expression of one or more proteins involved in the processing of the vitamin K dependent proteins. These processing proteins include paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide redactase (VKOR) and vitamin K dependent y-glutamyl carboxylase (VKGC)
Data Source
AI summary
The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent γ-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.